Enanta Pharmaceuticals, Inc. ENTA 深 沪
已收盘 10-02 16:00:00 美东时间
12.96
+0.120
+0.93%
华盛通- 最 高13.21
- 今 开13.20
- 成交量 74.80万股
- 最 低 12.58
- 昨 收 12.84
- 总市值 3.77亿
- 52周最高 17.15
- 市盈率 静 --
- 换手率 2.57%
- 52周最低 10.20
- 委 比 -16.67%
- 总股本 2912.54万
- 历史最高 127.77
- 量 比 2.27
- 振 幅 4.91%
- 历史最低 4.09
- 每 手 1
- 风险率 1.25%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 汽车地带绩后遭10家机构降目标价！最低看至3000美元；美光、微软、Meta齐获看多
今日重点评级关注：Leerink Partners：维持塞德斯医疗"跑赢大市"评级，目标价从70美元升至88美元；HC Wainwright & Co.：维持TriSalus Life Sciences"买入"评级，目标价从11美元升至12美元
09-24 16:10
HC Wainwright & Co. Reiterates Buy on Enanta Pharma, Maintains $20 Price Target
HC Wainwright & Co. analyst Brandon Folkes reiterates Enanta Pharma (NASDAQ:ENTA) with a Buy and maintains $20 price target.
09-23 18:45
Enanta Pharmaceuticals Establishes Flexible At-The-Market Offering
An update from Enanta Pharmaceuticals ( ($ENTA) ) is now available. On July 2, ...
07-03 05:18
Enanta Pharmaceuticals Enters Open Market Sale Agreement With Jefferies; May Offer And Sell Up To $75M Of Common Stock Through Jefferies
Enanta Pharmaceuticals Enters Open Market Sale Agreement With Jefferies; May Offer And Sell Up To $75M Of Common Stock Through Jefferies
07-03 04:58
美股大行评级 | 美银上调美光科技目标价从950美元升至1500美元，上调迈威尔科技目标价从240美元升至365美元
今日重点评级关注：摩根士丹利：维持杜邦"标配"评级，目标价从52美元升至156美元；蒙特利尔银行：维持Taysha Gene Therapies"跑赢大市"评级，目标价从10美元升至14美元
06-24 14:08
Enanta Faces Patent Setback in Paxlovid Litigation
The latest announcement is out from Enanta Pharmaceuticals ( ($ENTA) ). Enanta ...
06-24 06:43
AbbVie, Enanta announce EU label expansion for hepatitis C therapy, Maviret
AbbVie (ABBV) and Enanta Pharmaceuticals (ENTA) announced on Tuesday that the European Commission has approved a label expansion for their jointly developed hepatitis C therapy, Maviret. Accordingly, ...
06-23 19:34
Enanta Pharma Advances Zelicapavir Into Registrational Phase 2b/3 Clinical Trial In Adults At High Risk Of Severe Outcomes From RSV Infection After End-Of-Phase 2 Meeting With FDA
Registrational Ph2b/3 Trial of Zelicapavir to Initiate in High-Risk Adults with RSV in 4Q 2026, with Topline Phase 2b Data Expected in 2027 Phase 2b Trial of Zelicapavir to Initiate in Pediatric Patients with RSV in 3Q 2026, with Topline Data Expected in 2027 Enanta Pharmaceuticals, Inc. (NASDAQ:ENT...
06-18 19:06
Enanta将出席Jefferies全球医疗大会 聚焦RSV与免疫管线进展
Enanta Pharmaceuticals周四宣布，公司将出席即将举行的Jefferies全球医疗大会，与投资者分享其在呼吸道合胞病毒治疗和免疫学领域的最...
05-28 23:17
